Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

A randomized controlled field trial of iBsafe-a novel child safety game app.

Dixon CA, Ammerman RT, Johnson BL, Lampe C, Hart KW, Lindsell CJ, Mahabee-Gittens EM.

Mhealth. 2019 Jan 26;5:3. doi: 10.21037/mhealth.2019.01.02. eCollection 2019.

2.

Enzyme replacement therapy outcomes across the disease spectrum: findings from the mucopolysaccharidosis VI Clinical Surveillance Program.

Harmatz PR, Lampe C, Parini R, Sharma R, Teles EL, Johnson J, Sivam D, Sisic Z.

J Inherit Metab Dis. 2019 Mar 4. doi: 10.1002/jimd.12079. [Epub ahead of print]

PMID:
30834539
3.

Künstliche Intelligenz zur diagnostischen Unterstützung ausgewählter seltener lysosomaler Speichererkrankungen: Ergebnisse einer Pilotstudie.

Sieg AL, Martin Das A, Maria Muschol N, Köhn A, Lampe C, Kortum X, Mehmecke S, Blöß S, Lechner W, Klawonn F, Grigull L.

Klin Padiatr. 2019 Mar;231(2):60-66. doi: 10.1055/a-0816-5681. Epub 2019 Jan 10. German.

PMID:
30630212
4.

International working group identifies need for newborn screening for mucopolysaccharidosis type I but states that existing hurdles must be overcome.

Parini R, Broomfield A, Cleary MA, De Meirleir L, Di Rocco M, Fathalla WM, Guffon N, Lampe C, Lund AM, Scarpa M, Tylki-Szymańska A, Zeman J.

Acta Paediatr. 2018 Dec;107(12):2059-2065. doi: 10.1111/apa.14587. Epub 2018 Oct 23. Review.

5.

Spinal cord issues in adult patients with MPS: transition of care survey.

Ghotme KA, Alvarado-Gomez F, Lampe C, White KK, Solano-Villareal M, Giugliani R, Harmatz PR.

Childs Nerv Syst. 2018 Sep;34(9):1759-1765. doi: 10.1007/s00381-018-3834-6. Epub 2018 May 27.

PMID:
29804213
6.

Easy-to-use algorithm would provide faster diagnoses for mucopolysaccharidosis type I and enable patients to receive earlier treatment.

Tylki-Szymańska A, De Meirleir L, Di Rocco M, Fathalla WM, Guffon N, Lampe C, Lund AM, Parini R, Wijburg FA, Zeman J, Scarpa M.

Acta Paediatr. 2018 Aug;107(8):1402-1408. doi: 10.1111/apa.14417.

7.

Stand-alone craniocervical decompression is feasible in children with mucopolysaccharidosis type I, IVA, and VI.

Krenzlin H, Ta-Chih T, Lampe C, Lampe C, Knuf M, Horn P, Schwarz M.

Spine J. 2018 Aug;18(8):1455-1459. doi: 10.1016/j.spinee.2018.04.002. Epub 2018 Apr 9.

PMID:
29649608
8.

The Xanthomonas effector XopL uncovers the role of microtubules in stromule extension and dynamics in Nicotiana benthamiana.

Erickson JL, Adlung N, Lampe C, Bonas U, Schattat MH.

Plant J. 2018 Mar;93(5):856-870. doi: 10.1111/tpj.13813. Epub 2018 Feb 2.

9.

Practical management of behavioral problems in mucopolysaccharidoses disorders.

Escolar ML, Jones SA, Shapiro EG, Horovitz DDG, Lampe C, Amartino H.

Mol Genet Metab. 2017 Dec;122S:35-40. doi: 10.1016/j.ymgme.2017.09.010. Epub 2017 Sep 27. Review.

10.

Surgical management of neurological manifestations of mucopolysaccharidosis disorders.

Alden TD, Amartino H, Dalla Corte A, Lampe C, Harmatz PR, Vedolin L.

Mol Genet Metab. 2017 Dec;122S:41-48. doi: 10.1016/j.ymgme.2017.09.011. Epub 2017 Sep 28. Review.

11.

[Lysosomal Storage Diseases: Challenges in Multiprofessional Patient Care with Enzyme Replacement Therapy].

Das AM, Lagler F, Beck M, Scarpa M, Lampe C.

Klin Padiatr. 2017 May;229(3):168-174. doi: 10.1055/s-0043-103088. Epub 2017 May 2. German.

PMID:
28464188
12.

The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

Harmatz P, Hendriksz CJ, Lampe C, McGill JJ, Parini R, Leão-Teles E, Valayannopoulos V, Cole TJ, Matousek R, Graham S, Guffon N, Quartel A; MPS VI Study Group.

Mol Genet Metab. 2017 Sep;122(1-2):107-112. doi: 10.1016/j.ymgme.2017.03.008. Epub 2017 Mar 31.

13.

The ethical framework for performing research with rare inherited neurometabolic disease patients.

Giannuzzi V, Devlieger H, Margari L, Odlind VL, Ragab L, Bellettato CM, D'Avanzo F, Lampe C, Cassis L, Cortès-Saladelafont E, Cazorla ÁG, Barić I, Cvitanović-Šojat L, Fumić K, Dali CI, Bartoloni F, Bonifazi F, Scarpa M, Ceci A.

Eur J Pediatr. 2017 Mar;176(3):395-405. doi: 10.1007/s00431-017-2852-9. Epub 2017 Jan 16. Review.

14.

Erratum to: Review and evaluation of the methodological quality of the existing guidelines and recommendations for inherited neurometabolic disorders.

Cassis L, Cortès-Saladelafont E, Molero-Luis M, Yubero D, González MJ, Ormazábal A, Fons C, Jou C, Sierra C, Ponce EC, Ramos F, Armstrong J, O'Callaghan MM, Casado M, Montero R, Meavilla-Olivas S, Artuch R, Barić I, Bartoloni F, Bellettato CM, Bonifazi F, Ceci A, Cvitanović-Šojat L, Dali CI, D'Avanzo F, Fumic K, Giannuzzi V, Lampe C, Scarpa M, Garcia-Cazorla Á.

Orphanet J Rare Dis. 2016 Nov 3;11(1):147. No abstract available.

15.

Heart and Cardiovascular Involvement in Patients with Mucopolysaccharidosis Type IVA (Morquio-A Syndrome).

Kampmann C, Abu-Tair T, Gökce S, Lampe C, Reinke J, Mengel E, Hennermann JB, Wiethoff CM.

PLoS One. 2016 Sep 9;11(9):e0162612. doi: 10.1371/journal.pone.0162612. eCollection 2016.

16.

Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issues.

Hendriksz CJ, Berger KI, Lampe C, Kircher SG, Orchard PJ, Southall R, Long S, Sande S, Gold JI.

Orphanet J Rare Dis. 2016 Aug 26;11(1):119. doi: 10.1186/s13023-016-0503-2. Review.

17.

Cervical cord compression in mucopolysaccharidosis VI (MPS VI): Findings from the MPS VI Clinical Surveillance Program (CSP).

Solanki GA, Sun PP, Martin KW, Hendriksz CJ, Lampe C, Guffon N, Hung A, Sisic Z, Shediac R, Harmatz PR; CSP Study Group.

Mol Genet Metab. 2016 Aug;118(4):310-8. doi: 10.1016/j.ymgme.2016.06.001. Epub 2016 Jun 3.

18.

Social Media Analyses for Social Measurement.

Schober MF, Pasek J, Guggenheim L, Lampe C, Conrad FG.

Public Opin Q. 2016 Spring;80(1):180-211. Epub 2016 Jan 13.

19.

Review and evaluation of the methodological quality of the existing guidelines and recommendations for inherited neurometabolic disorders.

Cassis L, Cortès-Saladelafont E, Molero-Luis M, Yubero D, González MJ, Ormazábal A, Fons C, Jou C, Sierra C, Castejon Ponce E, Ramos F, Armstrong J, O'Callaghan MM, Casado M, Montero R, Meavilla-Olivas S, Artuch R, Barić I, Bartoloni F, Bellettato CM, Bonifazi F, Ceci A, Cvitanović-Šojat L, Dali CI, D'Avanzo F, Fumic K, Giannuzzi V, Lampe C, Scarpa M, Garcia-Cazorla Á.

Orphanet J Rare Dis. 2015 Dec 30;10:164. doi: 10.1186/s13023-015-0376-9. Review. Erratum in: Orphanet J Rare Dis. 2016 Nov 3;11(1):147.

20.

Alterations of mucosa of the larynx and hypopharynx in patients with mucopolysaccharidoses.

Keilmann A, Bendel F, Nospes S, Lampe C, Läßig AK.

J Laryngol Otol. 2016 Feb;130(2):194-200. doi: 10.1017/S0022215115003357. Epub 2015 Dec 17.

PMID:
26672641
21.

Comparison of Rebound Tonometry, Perkins Applanation Tonometry and Ocular Response Analyser in Mucopolysaccharidosis Patients.

Wasielica-Poslednik J, Butsch C, Lampe C, Elflein H, Lamparter J, Weyer V, Pitz S.

PLoS One. 2015 Aug 28;10(8):e0133586. doi: 10.1371/journal.pone.0133586. eCollection 2015.

22.

Neuronopathic lysosomal storage disorders: Approaches to treat the central nervous system.

Scarpa M, Bellettato CM, Lampe C, Begley DJ.

Best Pract Res Clin Endocrinol Metab. 2015 Mar;29(2):159-71. doi: 10.1016/j.beem.2014.12.001. Epub 2015 Jan 5. Review.

PMID:
25987170
23.

Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study.

Giugliani R, Lampe C, Guffon N, Ketteridge D, Leão-Teles E, Wraith JE, Jones SA, Piscia-Nichols C, Lin P, Quartel A, Harmatz P.

Am J Med Genet A. 2014 Aug;164A(8):1953-64. doi: 10.1002/ajmg.a.36584. Epub 2014 Apr 24.

24.

First experiences with the implementation of the European standard EN 62304 on medical device software for the quality assurance of a radiotherapy unit.

Höss A, Lampe C, Panse R, Ackermann B, Naumann J, Jäkel O.

Radiat Oncol. 2014 Mar 21;9:79. doi: 10.1186/1748-717X-9-79.

25.

Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey.

Hendriksz CJ, Lavery C, Coker M, Ucar SK, Jain M, Bell L, Lampe C.

Orphanet J Rare Dis. 2014 Mar 7;9:32. doi: 10.1186/1750-1172-9-32.

26.

Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series.

Lampe C, Bosserhoff AK, Burton BK, Giugliani R, de Souza CF, Bittar C, Muschol N, Olson R, Mendelsohn NJ.

J Inherit Metab Dis. 2014 Sep;37(5):823-9. doi: 10.1007/s10545-014-9686-7. Epub 2014 Mar 5.

27.

Enzyme Replacement Therapy in Mucopolysaccharidosis II Patients Under 1 Year of Age.

Lampe C, Atherton A, Burton BK, Descartes M, Giugliani R, Horovitz DD, Kyosen SO, Magalhães TS, Martins AM, Mendelsohn NJ, Muenzer J, Smith LD.

JIMD Rep. 2014;14:99-113. doi: 10.1007/8904_2013_289. Epub 2014 Feb 11.

28.

Mucopolysaccharidosis IVA (Morquio A syndrome) and VI (Maroteaux-Lamy syndrome): under-recognized and challenging to diagnose.

Lachman RS, Burton BK, Clarke LA, Hoffinger S, Ikegawa S, Jin DK, Kano H, Kim OH, Lampe C, Mendelsohn NJ, Shediac R, Tanpaiboon P, White KK.

Skeletal Radiol. 2014 Mar;43(3):359-69. doi: 10.1007/s00256-013-1797-y. Epub 2014 Jan 4.

29.

Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure.

Langereis EJ, Borgo A, Crushell E, Harmatz PR, van Hasselt PM, Jones SA, Kelly PM, Lampe C, van der Lee JH, Odent T, Sakkers R, Scarpa M, Schafroth MU, Struijs PA, Valayannopoulos V, White KK, Wijburg FA.

Orphanet J Rare Dis. 2013 Oct 3;8:155. doi: 10.1186/1750-1172-8-155. Review.

30.

Mucopolysaccharidosis VI: cardiac involvement and the impact of enzyme replacement therapy.

Kampmann C, Lampe C, Whybra-Trümpler C, Wiethoff CM, Mengel E, Arash L, Beck M, Miebach E.

J Inherit Metab Dis. 2014 Mar;37(2):269-76. doi: 10.1007/s10545-013-9649-4. Epub 2013 Sep 24.

PMID:
24062198
31.

Illness perception and clinical treatment experiences in patients with M. Maroteaux-Lamy (mucopolysaccharidosis type VI) and a Turkish migration background in Germany.

Dilger H, Leissner L, Bosanska L, Lampe C, Plöckinger U.

PLoS One. 2013 Jun 24;8(6):e66804. doi: 10.1371/journal.pone.0066804. Print 2013.

32.

Measuring corneal clouding in patients suffering from mucopolysaccharidosis with the Pentacam densitometry programme.

Elflein HM, Hofherr T, Berisha-Ramadani F, Weyer V, Lampe C, Beck M, Pitz S.

Br J Ophthalmol. 2013 Jul;97(7):829-33. doi: 10.1136/bjophthalmol-2012-302913. Epub 2013 May 17.

PMID:
23685998
33.

Mucopolysaccharidoses and other lysosomal storage diseases.

Lampe C, Bellettato CM, Karabul N, Scarpa M.

Rheum Dis Clin North Am. 2013 May;39(2):431-55. doi: 10.1016/j.rdc.2013.03.004. Review.

PMID:
23597973
34.

Development of a Scoring System to Evaluate the Severity of Craniocervical Spinal Cord Compression in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome).

Möllmann C, Lampe CG, Müller-Forell W, Scarpa M, Harmatz P, Schwarz M, Beck M, Lampe C.

JIMD Rep. 2013;11:65-72. doi: 10.1007/8904_2013_223. Epub 2013 Apr 12.

35.

Alterations in speech and voice in patients with mucopolysaccharidoses.

Nakarat T, Läßig AK, Lampe C, Keilmann A.

Logoped Phoniatr Vocol. 2014 Apr;39(1):30-7. doi: 10.3109/14015439.2013.776630. Epub 2013 Mar 21.

PMID:
23516972
36.

Craniocervical decompression in patients with mucopolysaccharidosis VI: development of a scoring system to determine indication and outcome of surgery.

Lampe C, Lampe C, Schwarz M, Müller-Forell W, Harmatz P, Mengel E.

J Inherit Metab Dis. 2013 Nov;36(6):1005-13. doi: 10.1007/s10545-013-9591-5. Epub 2013 Feb 14.

PMID:
23408180
37.

Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): presentation, diagnosis and management.

Solanki GA, Martin KW, Theroux MC, Lampe C, White KK, Shediac R, Lampe CG, Beck M, Mackenzie WG, Hendriksz CJ, Harmatz PR.

J Inherit Metab Dis. 2013 Mar;36(2):339-55. doi: 10.1007/s10545-013-9586-2. Epub 2013 Feb 6. Review.

38.

A multinational, multidisciplinary consensus for the diagnosis and management of spinal cord compression among patients with mucopolysaccharidosis VI.

Solanki GA, Alden TD, Burton BK, Giugliani R, Horovitz DD, Jones SA, Lampe C, Martin KW, Ryan ME, Schaefer MK, Siddiqui A, White KK, Harmatz P.

Mol Genet Metab. 2012 Sep;107(1-2):15-24. doi: 10.1016/j.ymgme.2012.07.018. Epub 2012 Jul 21. Review.

39.

A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations.

Herzog A, Hartung R, Reuser AJ, Hermanns P, Runz H, Karabul N, Gökce S, Pohlenz J, Kampmann C, Lampe C, Beck M, Mengel E.

Orphanet J Rare Dis. 2012 Jun 7;7:35. doi: 10.1186/1750-1172-7-35.

40.

Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series.

Thümler A, Miebach E, Lampe C, Pitz S, Kamin W, Kampmann C, Link B, Mengel E.

J Inherit Metab Dis. 2012 Nov;35(6):1071-9. doi: 10.1007/s10545-012-9474-1. Epub 2012 Mar 23.

PMID:
22441840
41.

Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP).

Hendriksz CJ, Giugliani R, Harmatz P, Lampe C, Martins AM, Pastores GM, Steiner RD, Leão Teles E, Valayannopoulos V; CSP Study Group.

J Inherit Metab Dis. 2013 Mar;36(2):373-84. doi: 10.1007/s10545-011-9410-9. Epub 2011 Nov 30.

PMID:
22127392
42.

Attenuated mucopolysaccharidosis: are you missing this debilitating condition?

Lampe C.

Rheumatology (Oxford). 2012 Mar;51(3):401-2. doi: 10.1093/rheumatology/ker375. Epub 2011 Nov 28. No abstract available.

PMID:
22123993
43.

Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease.

Scarpa M, Almássy Z, Beck M, Bodamer O, Bruce IA, De Meirleir L, Guffon N, Guillén-Navarro E, Hensman P, Jones S, Kamin W, Kampmann C, Lampe C, Lavery CA, Teles EL, Link B, Lund AM, Malm G, Pitz S, Rothera M, Stewart C, Tylki-Szymańska A, van der Ploeg A, Walker R, Zeman J, Wraith JE; Hunter Syndrome Europena Expert Council.

Orphanet J Rare Dis. 2011 Nov 7;6:72. doi: 10.1186/1750-1172-6-72.

44.

Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey.

Mendelsohn NJ, Harmatz P, Bodamer O, Burton BK, Giugliani R, Jones SA, Lampe C, Malm G, Steiner RD, Parini R; Hunter Outcome Survey Investigators.

Genet Med. 2010 Dec;12(12):816-22. doi: 10.1097/GIM.0b013e3181f6e74d.

PMID:
21045710
45.

It's complicated: Facebook users' political participation in the 2008 election.

Vitak J, Zube P, Smock A, Carr CT, Ellison N, Lampe C.

Cyberpsychol Behav Soc Netw. 2011 Mar;14(3):107-14. doi: 10.1089/cyber.2009.0226. Epub 2010 Jul 22.

PMID:
20649449
46.

Sterilization of products contaminated with Pyronema domesticum.

Lampe CM, Hansen JM, Rymer TM, Sargent H.

Biomed Instrum Technol. 2009 Nov-Dec;43(6):489-97.

PMID:
20041540
47.

Emergency medicine subinternship: does a standard clinical experience improve performance outcomes?

Lampe CJ, Coates WC, Gill AM.

Acad Emerg Med. 2008 Jan;15(1):82-5. doi: 10.1111/j.1553-2712.2007.00005.x.

48.

Supraventricular tachycardia with two VA intervals: what is the mechanism?

Nesbitt WH, Lampe C, Lustgarten D, Obel OA.

Pacing Clin Electrophysiol. 2007 Feb;30(2):253-5. No abstract available.

PMID:
17338723
49.

Dopaminergic modulation of long-lasting direct current-induced cortical excitability changes in the human motor cortex.

Nitsche MA, Lampe C, Antal A, Liebetanz D, Lang N, Tergau F, Paulus W.

Eur J Neurosci. 2006 Mar;23(6):1651-7.

PMID:
16553629
50.

No correlation between moving phosphene and motor thresholds: a transcranial magnetic stimulation study.

Antal A, Nitsche MA, Kincses TZ, Lampe C, Paulus W.

Neuroreport. 2004 Feb 9;15(2):297-302.

PMID:
15076756

Supplemental Content

Support Center